Current Report Filing (8-k)
04 April 2023 - 6:12AM
Edgar (US Regulatory)
0001837412
false
0001837412
2023-03-28
2023-03-28
0001837412
SLGC:CommonStock0.0001ParValuePerShareMember
2023-03-28
2023-03-28
0001837412
SLGC:WarrantsEachExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember
2023-03-28
2023-03-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or Section 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported): March 28, 2023
SomaLogic, Inc.
(Exact name of registrant
as specified in its charter)
Delaware |
|
001-40090 |
|
85-4298912 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
2945
Wilderness Place, Boulder,
Colorado |
|
80301 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone
number, including area code: (303) 625-9000
Not Applicable
(Former name or former
address, if changed since last report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following
provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section
12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on
which registered |
Common Stock, $0.0001 par value per share |
|
SLGC |
|
The NASDAQ Stock Market LLC |
Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share |
|
SLGCW |
|
The NASDAQ Stock Market LLC |
Indicate by check mark
whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On March
28, 2023, SomaLogic Operating Co., Inc., a wholly-owned subsidiary of SomaLogic, Inc. (the “Company”), and Shaun Blakeman,
the Company’s Chief Financial Officer, entered into a retention agreement (the “Retention Agreement”). Pursuant to the
Retention Agreement, Mr. Blakeman is eligible to receive a cash retention bonus (the “Bonus”) from the Company in consideration
for Mr. Blakeman’s continued employment through specified dates. The Bonus is payable in two installments, each equal to three months
of Mr. Blakeman’s annual base pay, or $117,500 per installment, on the first payroll date following each of September 16, 2023 and
March 16, 2024 (each, a “Retention Date”), subject to Mr. Blakeman’s continued employment through the applicable
Retention Date. If Mr. Blakeman is involuntarily terminated by the Company prior to either Retention Date, the remaining portion of the
Bonus will accelerate and become payable to Mr. Blakeman. This description of the Retention Agreement is a summary and is qualified in
its entirety by reference to the Retention Agreement which is attached hereto as Exhibit 10.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
SomaLogic, Inc. |
|
(Registrant) |
|
|
|
|
By: |
/s/ Ruben Gutierrez |
|
Name: |
Ruben Gutierrez |
|
Title: |
General Counsel |
April 3, 2023
2
CM Life Sciences II (NASDAQ:CMII)
Historical Stock Chart
From May 2024 to Jun 2024
CM Life Sciences II (NASDAQ:CMII)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about CM Life Sciences II Inc (NASDAQ): 0 recent articles
More Somalogic, Inc. News Articles